Dr. David Josephson, MD
Urology (Urology Physician)
8635 W 3rd St Ste 1
Los Angeles, CA 90048
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,511
Licensed in California since 2001, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
CA license A75701 (first issued 2001; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cedars-Sinai Medical Center Los Angeles, CA
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
Medical groups
- Tower Urology Inc (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,511
- Services billed
- 87,224
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, testosterone cypionate, 1 mg | 45,953 | 22 |
| Bcg live intravesical instillation, 1 mg | 5,401 | 19 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,700 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,717 | 1,039 |
| High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 1,350 | 26 |
| Insertion of needle into vein for collection of blood sample | 1,153 | 772 |
| Psa (prostate specific antigen) measurement, total | 1,101 | 736 |
| Testosterone (hormone) level, total | 1,085 | 730 |
| Kidney function blood test panel | 885 | 636 |
| Complete ultrasound scan of pelvis | 853 | 626 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Los Angeles, CA | 843 |
| Finasteride Other prescribers in Los Angeles, CA | 504 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Los Angeles, CA | 369 |
| Myrbetriq (mirabegron) Other prescribers in Los Angeles, CA | 355 |
| Gemtesa (vibegron) Other prescribers in Los Angeles, CA | 242 |
| Silodosin Other prescribers in Los Angeles, CA | 155 |
| Testosterone Other prescribers in Los Angeles, CA | 152 |
| Tadalafil | 147 |
| Cefuroxime (cefuroxime axetil) Other prescribers in Los Angeles, CA | 120 |
| Dutasteride Other prescribers in Los Angeles, CA | 99 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 40 payments worth $3,208 in total to this clinician.
| Intuitive Surgical, Inc. | $2,219 |
|---|---|
| Laborie Medical Technologies Corp. | $201 |
| Janssen Biotech, Inc. | $112 |
| Teleflex LLC | $110 |
| Telix Pharmaceuticals | $100 |
| Ferring Pharmaceuticals Inc. | $94.01 |
| Pfizer Inc. | $68.06 |
| Astellas Pharma US Inc | $58.27 |
| Education | $2,000 |
|---|---|
| Food and Beverage | $1,208 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Intuitive Surgical, Inc. Jun 13, 2025 | Education Da Vinci Surgical System · SURGERY | $2,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $244,211 in research payments for these studies, mostly to the institutions running them.
- Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics · Completed · NCT06604442 - Pylarify pet-ct or pet-mri in men with favorable intermediate risk -fir- prostate cancer -mirror
Progenics Pharmaceuticals, Inc. - A randomized,double blind,placebo controlled,phase third study of adjuvant saruparib AZD5305 in patients with bracam localized high risk prostate cancer receiving radiotherapy with aqndrogen deprivation therapy evo p…
AstraZeneca UK Limited - The utility of psma-pet imaging for detecting early metastatic prostate cancer in men with high gc decipher test scores: a sub-aim of the vandaam study (mcc #18523)
Progenics Pharmaceuticals, Inc. - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.